ShouTi welcomes addition of Dan Welch to its Board of Directors as Chairman

– USA, CA –  ShouTi Inc., a clinical-stage biopharmaceutical company replacing biologics with world-class small molecule medicines using advanced computational and structure-based technology, today announced the appointment of Dan Welch as Chairman of the board of directors.

“It is a true privilege to welcome Dan to ShouTi as Chairman of our board. As an industry veteran with an outstanding track record in guiding companies across all stages of development and commercialization, Dan’s leadership will be invaluable as we grow the company and ensure our life-changing medicines reach patients who are waiting,” said CEO, Dr. Raymond Stevens.

About Daniel Welch

Dan Welch is a distinguished life sciences executive, with over 40 years in the business of developing and commercializing medicines across both multinational pharmaceutical and biotechnology companies. He was Chairman, President, and CEO of InterMune until its $8.3 billion acquisition by Roche in 2014. Before InterMune, he was Chairman and CEO of Triangle Pharmaceuticals, which was acquired by Gilead in 2003. Before Triangle, he was President of Biopharmaceuticals at Elan Corporation where he was responsible for its worldwide pharmaceutical operations, R&D, and diagnostics businesses. From 1987 to 2000, he served in various senior management roles at Sanofi, including General Manager, VP of Worldwide Marketing, and COO of the U.S. business. Mr. Welch has played leadership roles in the development and commercialization of several blockbuster pharmaceutical brands, including Plavix, Tysabri, Eloxatin, Avapro, emtricitabine, and Esbriet. He is an experienced board director, serving on 13 boards over his career. Mr. Welch presently serves as Chairman of Ultragenyx Pharmaceutical (NASDAQ: RARE), Chairman of Nuvation Bio (NYSE: NUVB), Executive Chairman of Levo Therapeutics, Executive Chairman of InCarda Therapeutics, and Director of Seagen (NASDAQ: SGEN). He also spent time in biotech venture capital as Executive Partner at Sofinnova Investments, a leading Bay Area biotech VC firm.

Dan Welch, commented “I’m excited to join Ray and his proven team at ShouTi as Chairman of the board to help guide the company’s evolution as it works to design and develop world-class medicines with tremendous patient impact. ShouTi’s integrated global approach and its powerful, validated suite of cutting-edge drug discovery technologies holds the real possibility for positive, widespread impact for patients suffering from chronic illnesses. I look forward to working with their seasoned leadership team, utilizing my operational and commercial experience to further propel the company’s growth and success.”

Mr. Welch earned a B.A. from the University of Miami and an M.B.A. from the University of North Carolina.

About ShouTi

ShouTi develops life-changing medicines for patients using advanced computational and structure-based technology. The company’s platform combines the latest advancements in computational chemistry, visualization of molecular interactions, and data integration to design orally available, superior medicines that overcome current limitations of biologic and peptide drugs. ShouTi is advancing its clinical-stage pipeline of differentiated treatments focused on chronic diseases with high unmet needs, including cardiovascular, metabolic, and pulmonary conditions. The ShouTi team’s deep and proven experience with complex biological targets and mechanisms, structure-based drug design, and global drug discovery and development enables the company’s vision: to design and develop world-class medicines with high patient impact and broad commercial opportunity.

For more information: https://shoutipharma.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.